Bispecific antigen binding molecules that bind HER2, and methods of use thereof

US11958910B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Julian Andreev · Sleepy Hollow, US
• Andres Perez Bay · Cos Cob, US
• Christopher Daly · New York, US
• Frank Delfino · Poughquag, US
• Amy Han · Hockessin, US
• Thomas Nittoli · Pearl River, US
• William Olson · Ossining, US
• Gavin Thurston · Briarcliff Manor, US

Key dates

• Filing date: Feb 26, 2021
• Grant date: Apr 16, 2024
• Expiry date: Oct 9, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.